1. Home
  2. KALV vs IHRT Comparison

KALV vs IHRT Comparison

Compare KALV & IHRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo KalVista Pharmaceuticals Inc.

KALV

KalVista Pharmaceuticals Inc.

HOLD

Current Price

$15.48

Market Cap

757.7M

Sector

Health Care

ML Signal

HOLD

Logo iHeartMedia Inc.

IHRT

iHeartMedia Inc.

HOLD

Current Price

$2.65

Market Cap

552.6M

ML Signal

HOLD

Company Overview

Basic Information
Metric
KALV
IHRT
Founded
N/A
1974
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Broadcasting
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
757.7M
552.6M
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
KALV
IHRT
Price
$15.48
$2.65
Analyst Decision
Strong Buy
Hold
Analyst Count
5
3
Target Price
$30.00
$4.33
AVG Volume (30 Days)
721.4K
796.4K
Earning Date
03-25-2026
03-02-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$50,000,000.00
N/A
Revenue This Year
N/A
$7.45
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
495.66
N/A
52 Week Low
$9.83
$0.95
52 Week High
$19.00
$5.44

Technical Indicators

Market Signals
Indicator
KALV
IHRT
Relative Strength Index (RSI) 45.58 34.68
Support Level $14.59 $2.62
Resistance Level $16.49 $3.37
Average True Range (ATR) 0.98 0.26
MACD -0.06 -0.03
Stochastic Oscillator 13.35 10.71

Price Performance

Historical Comparison
KALV
IHRT

About KALV KalVista Pharmaceuticals Inc.

KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.

About IHRT iHeartMedia Inc.

iHeartMedia Inc is a United States-based audio media company. The company operates through the segments of the Multiplatform Group, the Digital Audio Group, and the Audio & Media Services Group. The company derives prime revenue from the Multiplatform Group segment which includes the company's Broadcast radio, Networks and Sponsorships, and Events businesses. The Digital Audio Group segment includes all of the company's digital businesses, including podcasting; and the Audio & Media Services Group includes Katz Media Group, a full-service media representation business, and RCS Sound Software, a provider of scheduling and broadcast software and services.

Share on Social Networks: